Table 1.
Demographics and baseline characteristics of patients (full analysis set).
| Liztox Group (n = 98) | Botox Group (n = 97) | p-Value | |
|---|---|---|---|
| Age (years) | 59.2 ± 12.6 | 59.4 ± 11.2 | 0.8420 |
| Sex, n (%) | 0.9155 | ||
| Male | 67 (68.4) | 67 (69.1) | |
| Female | 31 (31.6) | 30 (30.9) | |
| Height (cm) | 164.8 ± 7.7 | 165.9 ± 8.2 | 0.3566 |
| Body weight (kg) | 67.9 ± 11.0 | 68.0 ± 12.1 | 0.8441 |
| BMI (kg/m2) | 24.9 ± 3.4 | 24.6 ± 3.1 | 0.6782 |
| Duration of spasticity (months) | 116.7 ± 80.3 | 106.4 ± 77.4 | 0.4196 |
| Previous BTX-A administration *, n (%) | - | ||
| Yes | 0 (0) | 0 (0) | |
| No | 98 (100) | 97 (100) | |
| DAS items, n (%) | 0.6039 | ||
| Hand hygiene | 21 (21.4) | 17 (17.5) | |
| Dressing | 3 (3.1) | 6 (6.2) | |
| Limb position | 71 (72.5) | 69 (71.1) | |
| Pain | 3 (3.1) | 5 (5.2) |
* Botulinum toxin administration within 3 months prior to screening.